echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: MRD dynamics during maintenance therapy help improve prognosis

    Blood: MRD dynamics during maintenance therapy help improve prognosis

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Residual lesion (MRD) evaluation can help guide the length


    MRD status at randomization showed independent prognostic value: median progression-free survival (PFS) in patients with MRD-negative (-) and MRD-positive (+) was 38.



    A landmark 14-month analysis showed that patients who switched from MRD+ status to MRD-status had longer PFS compared with patients with persistent MRD+ status (2-year PFS rate: 76.



    In patients with MRD+ at randomized grouping, Ixazomib maintenance therapy prolonged PFS compared to placebo (median PFS: 18.


    In summary, the findings show that the prognostic value of a single-time point MRD assessment is limited


    Original Source:

    Bruno Paiva, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.